Immune checkpoint inhibitors in non-small cell lung cancer – When should we dare to stop treatment?

Farastuk Bozorgmehr, Annette Müller,Justyna Rawluk, Maria Sianidou,Inn Chung,Cornelia Kropf-Sanchen

Lung cancer (Amsterdam, Netherlands)（2023）

引用 0|浏览5

暂无评分

摘要

•Currently, immune checkpoint inhibitors (ICI) are administered until progress.•In clinical trials appr. 25% of NSCLC patients complete a two-year ICI treatment.•Persistent response after fixed ICI period is observed in most patients.•Efficacy of ICI rechallenge needs to be determined.•In case of tumor response, fixed ICI therapy duration should be considered.

查看译文

关键词

CI,CHT,CT,ctDNA,DCR,HR,ICI,irAE,NSCLC,ORR,OS,PD,PET,PFS,PR,SD,TFI,TMB,trAE

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要